Impact of Exenatide on Sleep Duration
NCT01416649 · Completed
Last updated 2026-05-28This clinical trial tests whether the medication exenatide affects sleep duration and quality in adults with type 2 diabetes.
What this study is testing ClinicalTrials.gov NCT01416649 ↗
Description as written by the study sponsor.
This study investigates the effect of exenatide, a FDA approved medication for the treatment of type 2 diabetes on sleep duration and quality. Individuals with type 2 diabetes will be studied before and during treatment with Exenatide. Enrolled individuals will be asked to come to the University of Chicago for 3-4 outpatient visits over the course of 3-4 months.
Treatments tested
- Exenatide also known as The brand name of exenatide is Byetta. Drug
Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
| Main thing measured | Sleep duration and sleep efficiency |
|---|---|
| Sponsor | University of Chicago |
| Conditions studied | Type 2 Diabetes |
| GLP-1 drugs | exenatide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01416649 ↗